Lidak Pharmaceuticals said Tuesday that it has raised about$8.5 million from the exercise of 98.2 percent of its 5.75 millionoutstanding class A warrants. The company expects to net$8,158,000 after fees and expenses. The La Jolla, Calif.,company (NASDAQ:LDAKA) is focusing on commercializingLidakol, its treatment for herpes and other indications.
(c) 1997 American Health Consultants. All rights reserved.